| Date Filed | Type | Description |
| 10/12/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/25/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 02/01/2023 |
SC 13G/A
| Murchinson Ltd. reports a 0% stake in Humanigen, Inc. |
| 12/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/06/2022 |
8-K
| Quarterly results |
| 09/29/2022 |
8-K
| Quarterly results |
| 09/02/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/26/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/29/2022 |
4
| Buxton Cheryl (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 78,362 options to buy
@ $0.38, valued at
$29.8k
|
|
| 07/29/2022 |
4
| Hohneker John (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 63,195 options to buy
@ $0.38, valued at
$24k
|
|
| 07/29/2022 |
4
| BARLIANT RONALD (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 55,612 options to buy
@ $0.38, valued at
$21.1k
|
|
| 07/29/2022 |
4
| Kilcoyne Adrian (Chief Medical Officer) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 537,164 options to buy
@ $0.38, valued at
$204.1k
|
|
| 07/29/2022 |
4
| Chappell Dale (Chief Scientific Officer) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 518,205 options to buy
@ $0.38, valued at
$196.9k
|
|
| 07/29/2022 |
4
| Boehm Rainer J. (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 73,307 options to buy
@ $0.38, valued at
$27.9k
|
|
| 07/29/2022 |
4
| Jordan Edward P. (Chief Commercial Officer) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 455,010 options to buy
@ $0.38, valued at
$172.9k
|
|
| 07/29/2022 |
4
| MORRIS TIMOTHY E (COO and CFO) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 600,360 options to buy
@ $0.38, valued at
$228.1k
|
|
| 07/29/2022 |
4
| Xie Yili Kevin (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 83,418 options to buy
@ $0.38, valued at
$31.7k
|
|
| 07/29/2022 |
4
| Durrant Cameron (CEO) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 808,906 options to buy
@ $0.38, valued at
$307.4k
|
|
| 07/26/2022 |
8-K
| Quarterly results |
| 07/13/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
|